Immune and metabolic alterations in first episode psychosis (FEP) patients

the GET UP Group

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.

Original languageEnglish
Pages (from-to)315-324
Number of pages10
JournalBrain, Behavior, and Immunity
Volume70
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Psychotic Disorders
Ghrelin
Glucagon-Like Peptide 1
Plasminogen Activator Inhibitor 1
Glucagon
Vascular Endothelial Growth Factor A
Interleukin-17
Interleukin-8
Interleukin-6
Intercellular Signaling Peptides and Proteins
Nicotinamide Phosphoribosyltransferase
Psychotic Affective Disorders
Resistin
Chemokine CCL5
Metabolome
C-Peptide
Brain-Derived Neurotrophic Factor
Leptin
Principal Component Analysis
Interleukin-10

Keywords

  • Cytokines and chemokines
  • FEP
  • Ghrelin
  • GLP-1
  • Glucagon
  • IL-8
  • Metabolic markers
  • MIP-1b/CCL4
  • VEGF

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

Immune and metabolic alterations in first episode psychosis (FEP) patients. / the GET UP Group.

In: Brain, Behavior, and Immunity, Vol. 70, 01.05.2018, p. 315-324.

Research output: Contribution to journalArticle

@article{6575a1c43f974c1ca961a0086315c57c,
title = "Immune and metabolic alterations in first episode psychosis (FEP) patients",
abstract = "The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.",
keywords = "Cytokines and chemokines, FEP, Ghrelin, GLP-1, Glucagon, IL-8, Metabolic markers, MIP-1b/CCL4, VEGF",
author = "{the GET UP Group} and Luisella Bocchio-Chiavetto and Roberta Zanardini and Sarah Tosato and Mariacarla Ventriglia and Clarissa Ferrari and Chiara Bonetto and Antonio Lasalvia and Franco Giubilini and Angelo Fioritti and Francesca Pileggi and Michela Pratelli and Michele Pavanati and Angela Favaro and {De Girolamo}, Giovanni and Frisoni, {Giovanni Battista} and Mirella Ruggeri and Massimo Gennarelli",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bbi.2018.03.013",
language = "English",
volume = "70",
pages = "315--324",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Immune and metabolic alterations in first episode psychosis (FEP) patients

AU - the GET UP Group

AU - Bocchio-Chiavetto, Luisella

AU - Zanardini, Roberta

AU - Tosato, Sarah

AU - Ventriglia, Mariacarla

AU - Ferrari, Clarissa

AU - Bonetto, Chiara

AU - Lasalvia, Antonio

AU - Giubilini, Franco

AU - Fioritti, Angelo

AU - Pileggi, Francesca

AU - Pratelli, Michela

AU - Pavanati, Michele

AU - Favaro, Angela

AU - De Girolamo, Giovanni

AU - Frisoni, Giovanni Battista

AU - Ruggeri, Mirella

AU - Gennarelli, Massimo

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.

AB - The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.

KW - Cytokines and chemokines

KW - FEP

KW - Ghrelin

KW - GLP-1

KW - Glucagon

KW - IL-8

KW - Metabolic markers

KW - MIP-1b/CCL4

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85044128008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044128008&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2018.03.013

DO - 10.1016/j.bbi.2018.03.013

M3 - Article

AN - SCOPUS:85044128008

VL - 70

SP - 315

EP - 324

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -